Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)
Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)
Researchers are trying to find out more about the safety of a new treatment, Allogeneic
 (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs) which is
 still experimental, for Interstitial Lung Disease (ILD) associated with Connective Tissue
 Disorder (CTD).
Inclusion Criteria:

 -  Adults over 18 years of age and less than 80 years of age

 -  Both female and male

 -  Patients with new diagnosis of interstitial lung disease associated with connective
 tissue disorders, Antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis
 or idiopathic pneumonia with autoimmune features (IPAF) or established diagnosis of
 ILD associated with CTD under conventional therapy for at least 6 months but less than
 24 months, with no evidence of improvement.

 -  Competent and able to provide written informed consent, and ability to comply with
 protocol

 Exclusion Criteria:

 -  Patients with interstitial lung disease without evidence of a concomitant
 rheumatologic autoimmune disorder

 -  Exposure to rituximab or cyclophosphamide on the previous 2 months

 -  Severe interstitial lung disease defined by the presence of severe hypoxemia at rest
 (SO2 < 88% at rest)

 -  Clinical assessment that indicates active chronic infections such as osteomyelitis or
 active tuberculosis (TB), or acute infections such as pneumonia, active bronchitis,
 cellulitis, etc. or active solid tumors or hematologic malignancies

 -  Previous treatment with mesenchymal stem cells

 -  Clinically significant medical conditions within the six months before administration
 of BMD-MSCs: e.g. myocardial infarction, active angina, congestive heart failure or
 other conditions that would, in the opinion of the investigators, compromise the
 safety of the patient.

 -  Medical history of human immunodeficiency virus (HIV), Hepatitis B or C

 -  Abnormal complete blood count (CBC), creatinine, Aspartate aminotransferase (AST) or
 Alanine aminotransferase (ALT) at screening

 -  Pregnant or breast feeding

 -  Unwilling to agree to use acceptable contraception methods during participation in the
 trial

 -  Inability to provide informed consent